SCHEMBL6976528

SCHEMBL6976528

O=C1CC(CCCN2C(=O)c3ccccc3C2=O)=CC=C1C[C@@H](NS(=O)(=O)c1ccc2nc(Cl)sc2c1)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.42
MEN1 O00255 1/20 0.40
CYP2C9 P11712 1/20 0.40
KMT2A Q03164 1/20 0.40
MMP2 P08253 4/20 0.37
MMP9 P14780 3/20 0.37
MAPT P10636 2/20 0.36
MMP1 P03956 1/20 0.36
MMP14 P50281 1/20 0.36
ADAM17 P78536 1/20 0.36
ADAMTS5 Q9UNA0 1/20 0.35
MAPK1 P28482 1/20 0.35
TP53 P04637 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
ADORA2A P29274 1/20 0.34
ALOX15 P16050 1/20 0.34
NPC1 O15118 1/20 0.34
HPGD P15428 1/20 0.34
NFKB1 P19838 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5756026 0.85 PPARG (0.40) ALDH1A1MEN1CYP2C9KMT2AMAPT
SCHEMBL5756354 0.84 MAPT (0.40) ALDH1A1MEN1CYP2C9KMT2AMMP2
SCHEMBL5752915 0.80 ITGB3 (0.45) ALDH1A1MEN1CYP2C9KMT2AMMP2
SCHEMBL6976625 0.80 ALDH1A1 (0.38) ALDH1A1MEN1CYP2C9KMT2AMMP2
SCHEMBL6976961 0.74 PPARG (0.43) MEN1CYP2C9KMT2AMAPTTP53
SCHEMBL6976507 0.73 PPARG (0.43) MEN1CYP2C9KMT2AMAPTTP53
SCHEMBL6969845 0.69 PPARA (0.41) MEN1CYP2C9KMT2AMMP2MMP9
SCHEMBL6978363 0.68 PPARA (0.41) MEN1CYP2C9KMT2AMMP2MMP9
SCHEMBL6977358 0.67 KMT2A (0.46) ALDH1A1MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL5754509 0.67 ITGB3 (0.46) ALDH1A1MEN1CYP2C9KMT2AMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6548667-B2 For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase SAMSUNG ELECTRONICS CO. LTD. (KR) 2003-04-15 US disclosed
EP-1208092-A4 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2003-01-02 EP disclosed
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor SAMSUNG ELECTRONICS CO. LTD. (KR) 2002-11-14 US disclosed
EP-1208092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2002-05-29 EP disclosed
WO-2001077092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor MMP9, MMP3, MMP14 ALDH1A1 311/4885MEN1 2541/4885CYP2C9 874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.